Partners

ASX
LCT 0.041   Last updated EOD 10th December 2018
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Intellectual Property

LCT actively protects a range of intellectual property consisting in our core transplantation and encapsulation technologies technologies, our indication specific therapeutics and the use of designated pathogen free cells from a herd of Auckland Island pigs.

 

Our patents are grouped into series by the technology they apply to. We currently hold patents in a number of series across several jurisdictions including United States, Europe, New Zealand, Australia, Mexico, Singapore, South Africa and Russia.

 

LCT also has registered trademarks relating to LCT, NTCELL® and IMMUPEL.

 

Our IP lawyers are AJ Park in New Zealand and SeedIP in the United States.

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.